stockrow
Friday 6 November 2026
Export MBX’s income statement to Excel — free account
MBX Biosciences, Inc.
- EPS
- −34.5%
- Free cash flow
- −29.7%
Quarter to June 2026, against a year earlier
50.93
2.47
+5.10%
Follow MBX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 30 | 30 | 30 | 0.0% | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | (26) | (33) | (62) | (87) | (104) | +49.3% | ||||||
| EBT margin, % | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | (26) | (33) | (62) | (87) | (104) | +49.3% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | (39.18) | (31.96) | (5.82) | (2.38) | (2.41) | (60.7%) | ||||||
| Cash flow | — | — | — | — | — | — | (34.67) | (31.38) | (5.14) | (2.19) | (1.73) | (60.2%) | ||||||
| Capex | — | — | — | — | — | — | (0.66) | (0.13) | (0.08) | (0.05) | (0.05) | (56.9%) | ||||||
| Free cash flow | — | — | — | — | — | — | (35.33) | (31.51) | (5.22) | (2.24) | (1.79) | (60.1%) | ||||||
| Book value | — | — | — | — | — | — | (63.88) | (71.12) | 24.19 | 10.11 | 8.59 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | 1 | 1 | 11 | 37 | 41 | +279.7% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (23) | (32) | (55) | (80) | (83) | +51.2% | |||||
| Capex | — | — | — | — | — | — | 0 | 0 | (1) | (2) | (3) | +63.5% | ||||||
| Free cash flow | — | — | — | — | — | — | (24) | (32) | (56) | (82) | (85) | +51.5% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | 41 | 80 | 256 | 366 | 404 | +107.8% | |||||
| Net debt | — | — | — | — | — | — | (42) | (81) | (262) | (374) | (419) | +106.5% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | (43) | (72) | 257 | 369 | 410 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (50.38) | (35.11) | (26.61) | (31.25) | (26.6) pt | |||||
| ROIC | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | 0.00 | 56.60 | (66.95) | (27.76) | (33.17) | (27.8) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 36 | 43 | 63 | — | +32.3% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
MBX Biosciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ADMA ADMA Biologics Inc | $3.0B | 16.7× | 14.0× | +5.12% (above 0%: growing) | +46.67% (above 0%: growing) | +1,709.49% (above 0%: growing) | 70.81% | 48.02% | Compare |
| ZLAB Zai Lab Limited Unsponsored ADR | $2.6B | — (loss-making) | — (loss-making) | −6.79% (below 0%: shrinking) | n/m | −95.46% (below 0%: shrinking) | 0.00% | (58.20%) | Compare |
| XNCR Xencor, Inc. | $2.5B | — (loss-making) | — (loss-making) | +17.46% (above 0%: growing) | n/m | −52.91% (below 0%: shrinking) | 100.00% | (72.37%) | Compare |
| RCUS Arcus Biosciences, Inc. | $2.5B | — (loss-making) | — (loss-making) | −65.38% (below 0%: shrinking) | n/m | +9.28% (above 0%: growing) | 100.00% | (1,455.56%) | Compare |
| MBX MBX Biosciences, Inc. | $2.3B | — (loss-making) | — | — | n/m | −29.67% (below 0%: shrinking) | — | 0.00% | |
| PHVS Pharvaris N.V. | $2.3B | — (loss-making) | — | — | n/m | −17.31% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NAMS NewAmsterdam Pharma Company N.V. | $2.3B | — (loss-making) | — (loss-making) | +5,406.90% (above 0%: growing) | n/m | −21.76% (below 0%: shrinking) | 100.00% | (230.58%) | Compare |
| CLDX Celldex Therapeutics, Inc. | $2.2B | — (loss-making) | — (loss-making) | −96.83% (below 0%: shrinking) | n/m | −35.45% (below 0%: shrinking) | 100.00% | (366,468.18%) | Compare |
| RXRX Recursion Pharmaceuticals, Inc. | $2.2B | — (loss-making) | — (loss-making) | +258.49% (above 0%: growing) | n/m | +33.83% (above 0%: growing) | 45.85% | (663.95%) | Compare |
| Median of peers | $2.4B | — | — | +5.12% | — | −19.53% | 85.41% | (151.47%) |
Pay and ownership Proxy statement filed 22 April 2026
Ownership
Directors and executive officers, together
31.09%
Patrick J. Heron
14.02%
Entities affiliated with Frazier Life Sciences
13.98%
Entities affiliated with OrbiMed Advisors LLC
7.65%
Edward T. Mathers
7.64%
Entities affiliated with New Enterprise Associates
7.60%
Entities affiliated with Wellington Management Group LLP
7.04%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement